Ionis Pharmaceuticals, Inc. (IONS)


Bronstein, Gewirtz & Grossman, LLC is investigating potential claims on behalf of purchasers of Ionis Pharmaceuticals, Inc. ("Ionis" or "the Company") (NASDAQ: IONS). The investigation concerns whether Ionis and certain of its officers and/or directors have violated federal securities laws.


On March 22, 2021, post-market, Ionis issued a press release announcing that “its partner, Roche, has decided to discontinue dosing in the Phase III GENERATION HD1 study of tominersen in manifest Huntington's disease (HD).”  Ionis specified that “[t]he decision was based on the results of a pre-planned review of data from the Phase III study conducted by an unblinded Independent Data Monitoring Committee (iDMC).  While there were no new or emerging safety signals identified for tominersen, the iDMC made its recommendation based on the investigational therapy's potential benefit/risk profile for study participants.”  On this news, Ionis’s stock price fell $12.05 per share, or 21.66%, to close at $43.59 per share on March 23, 2021.


If you are aware of any facts relating to this investigation, or purchased Ionis shares, you can assist this investigation by visiting contacting the firm. You can also contact Peretz Bronstein or his Investor Relations Analyst, Yael Hurwitz of Bronstein, Gewirtz & Grossman, LLC: 212-697-6484. 

Bronstein, Gewirtz & Grossman, LLC is a corporate litigation boutique.  Our primary expertise is the aggressive pursuit of litigation claims on behalf of our clients.  In addition to representing institutions and other investor plaintiffs in class action security litigation, the firm’s expertise includes general corporate and commercial litigation, as well as securities arbitration. Attorney advertising. Prior results do not guarantee similar outcomes.

© 2020 Bronstein, Gewirtz & Grossman, LLC

  • Twitter Social Icon
  • LinkedIn

BG&G is not affiliated to any of these companies. All respective trademarks are owned by the respective companies.